← Leaderboards
Jack A. Syage
Immunogenics, Llc
$3,812,715
Attributed
$6,896,837
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2017–23$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,896,837 · 3
By mechanism
U44$3,225,052 · 1
R44$2,204,433 · 1
R33$1,467,352 · 1
Top collaborators
- Joseph A Murray7 shared
- David Matthew Maahs3 shared
Others in their field
Other Emerging Leaders on “Proteins”
- John Damon Chodera · Sloan-Kettering Inst Can Research$50,971,767
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Susan M Landau · University Of California Berkeley$47,252,026
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$40,723,314
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
Research focus
ProteinsSymptomsPharmaceutical PreparationsPlacebosSafetyStomachEnzymesExposure ToGlutenHistologicReduce SymptomsLeadEffective TherapySmall IntestinesDiariesEnrollmentAutoimmune DiseasesClinical TrialsDiagnosticGastrointestinalCeliac DiseaseDiagnosisAdherenceMeasurement
Grant awards (11)
A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease$728,593
U44 · FY2023 · AI · contact PI
A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease$200,524
U44 · FY2022 · AI · contact PI
A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease$998,618
U44 · FY2021 · AI · contact PI
A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease$933,572
R44 · FY2021 · DK · contact PI
A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease$998,228
U44 · FY2020 · AI · contact PI
A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease$977,604
R44 · FY2020 · DK · contact PI
Latiglutenase as a Treatment for Celiac Disease$259,102
R33 · FY2020 · AT · contact PI
A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease$299,089
U44 · FY2019 · AI · contact PI
A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease$293,257
R44 · FY2019 · DK · contact PI
Latiglutenase as a Treatment for Celiac Disease$615,254
R33 · FY2018 · AT · contact PI
Latiglutenase as a Treatment for Celiac Disease$592,996
R33 · FY2017 · AT · contact PI